CAS 127984-74-1|Lanreotide acetate
Introduction：Basic information about CAS 127984-74-1|Lanreotide acetate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lanreotide acetate | ||
|---|---|---|---|
| CAS Number | 127984-74-1 | Molecular Weight | 1156.375 |
| Density | / | Boiling Point | / |
| Molecular Formula | C56H73N11O12S2 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS08 | Signal Word | Warning |
Names
| Name | Somatuline |
|---|---|
| Synonym | More Synonyms |
Chemical & Physical Properties
| Molecular Formula | C56H73N11O12S2 |
|---|---|
| Molecular Weight | 1156.375 |
| Exact Mass | 1155.488159 |
| Appearance of Characters | white to off-white |
| InChIKey | PUDHBTGHUJUUFI-UHFFFAOYSA-N |
| SMILES | CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O |
| Storage condition | ?20°C |
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H361 |
| Precautionary Statements | P281 |
| Hazard Codes | Xn |
| Risk Phrases | 63 |
| Safety Phrases | 36/37 |
| RIDADR | NONH for all modes of transport |
Articles34
More Articles| [Drug therapy for acromegaly]. Orv. Hetil. 154(39) , 1527-34, (2013) Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Desp... | |
| Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3) , 354-62, (2013) Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeleta... | |
| Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient. Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013) We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and r... |
Synonyms
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxo-2-butanyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)-D-alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:1) |
| 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-, (4R,7S,10S,13R,16S,19R)-, acetate (1:1) (salt) |
| Somatuline |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt) |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| Somatuline LP |
| (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pe |
| lanreotide acetate |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt) |
| (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6, |
| Somatuline LA |
| ntaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt) |
| Somatuline Autogel |
| 1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxypheny |
